Immunovant annual net debt
2020
2021
2022
2023
2024
2025
2026
Immunovant Net Debt Growth & History (IMVT)
Immunovant's net debt was −$902.0M for fiscal 2026.
View full Immunovant company overviewImmunovant annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$902.0M | −$188.2M | — |
| 2025 | 2025-03-31 | −$713.9M | −$78.6M | — |
| 2024 | 2024-03-31 | −$635.2M | −$259.9M | — |
| 2023 | 2023-03-31 | −$375.3M | $116.1M | — |
| 2022 | 2022-03-31 | −$491.5M | −$94.7M | — |
| 2021 | 2021-03-31 | −$396.7M | −$296.2M | — |
| 2020 | 2020-03-31 | −$100.6M | — | — |
Immunovant quarterly net debt
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q4.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | −$902.0M | −$188.2M | — |
| Q4 2025 | 2025-03-31 | −$713.9M | −$78.6M | — |
| Q3 2025 | 2024-12-31 | −$374.7M | $316.0M | — |
| Q2 2025 | 2024-09-30 | −$472.9M | −$203.6M | — |
| Q1 2025 | 2024-06-30 | −$559.9M | −$230.9M | — |
| Q4 2024 | 2024-03-31 | −$635.2M | −$259.9M | — |
| Q3 2024 | 2023-12-31 | −$690.6M | −$259.5M | — |
| Q2 2024 | 2023-09-30 | −$269.3M | $134.7M | — |
| Q1 2024 | 2023-06-30 | −$329.0M | $96.1M | — |
| Q4 2023 | 2023-03-31 | −$375.3M | $116.1M | — |
| Q3 2023 | 2022-12-31 | −$431.1M | $94.8M | — |
| Q2 2023 | 2022-09-30 | −$404.0M | $153.9M | — |
| Q1 2023 | 2022-06-30 | −$425.1M | −$49.2M | — |
| Q4 2022 | 2022-03-31 | −$491.5M | −$94.7M | — |
| Q3 2022 | 2021-12-31 | −$525.9M | −$107.4M | — |
| Q2 2022 | 2021-09-30 | −$557.9M | −$117.3M | — |
| Q1 2022 | 2021-06-30 | −$375.9M | −$99.9M | — |
| Q4 2021 | 2021-03-31 | −$396.7M | −$296.2M | — |
| Q3 2021 | 2020-12-31 | −$418.5M | — | — |
| Q2 2021 | 2020-09-30 | −$440.6M | — | — |
| Q1 2021 | 2020-06-30 | −$276.1M | — | — |
| Q4 2020 | 2020-03-31 | −$100.6M | — | — |
Immunovant net debt trends
Over the last five fiscal years, Immunovant's net debt decreased from −$396.7M to −$902.0M, a change of −$505.3M. The latest reported quarter, Q4 2026, shows −$902.0M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant source filings ↗